CN1332974C - 抗雌激素甾族化合物、有关的药学组合物和使用方法 - Google Patents

抗雌激素甾族化合物、有关的药学组合物和使用方法 Download PDF

Info

Publication number
CN1332974C
CN1332974C CNB988137011A CN98813701A CN1332974C CN 1332974 C CN1332974 C CN 1332974C CN B988137011 A CNB988137011 A CN B988137011A CN 98813701 A CN98813701 A CN 98813701A CN 1332974 C CN1332974 C CN 1332974C
Authority
CN
China
Prior art keywords
alkyl
hydrogen
arh
aryl
norpregna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988137011A
Other languages
English (en)
Chinese (zh)
Other versions
CN1291196A (zh
Inventor
田辺正人
R·H·彼得斯
赵张婉如
钟灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of CN1291196A publication Critical patent/CN1291196A/zh
Application granted granted Critical
Publication of CN1332974C publication Critical patent/CN1332974C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNB988137011A 1997-12-24 1998-12-23 抗雌激素甾族化合物、有关的药学组合物和使用方法 Expired - Fee Related CN1332974C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/998,877 US6054446A (en) 1997-12-24 1997-12-24 Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US08/998,877 1997-12-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200710128699XA Division CN101130567B (zh) 1997-12-24 1998-12-23 新的抗雌激素甾族化合物、有关的药学组合物和使用方法

Publications (2)

Publication Number Publication Date
CN1291196A CN1291196A (zh) 2001-04-11
CN1332974C true CN1332974C (zh) 2007-08-22

Family

ID=25545637

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988137011A Expired - Fee Related CN1332974C (zh) 1997-12-24 1998-12-23 抗雌激素甾族化合物、有关的药学组合物和使用方法
CN200710128699XA Expired - Lifetime CN101130567B (zh) 1997-12-24 1998-12-23 新的抗雌激素甾族化合物、有关的药学组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200710128699XA Expired - Lifetime CN101130567B (zh) 1997-12-24 1998-12-23 新的抗雌激素甾族化合物、有关的药学组合物和使用方法

Country Status (14)

Country Link
US (3) US6054446A (enExample)
EP (4) EP1847548A3 (enExample)
JP (4) JP2001525855A (enExample)
KR (1) KR100464739B1 (enExample)
CN (2) CN1332974C (enExample)
AU (1) AU749597C (enExample)
BR (1) BR9814435A (enExample)
CA (1) CA2281844C (enExample)
DE (2) DE69839893D1 (enExample)
HU (1) HUP0100136A3 (enExample)
IL (1) IL136972A0 (enExample)
NO (1) NO317978B1 (enExample)
RU (1) RU2233288C2 (enExample)
WO (1) WO1999033859A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
MXPA02001547A (es) * 1999-08-13 2002-07-02 Wieland Heinrich Extractos de glicinas de soya e inhibidores de aromatasa para afectar positivamente colageno.
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6784170B2 (en) 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
EP1284272A4 (en) 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
WO2001099009A2 (en) * 2000-06-20 2001-12-27 United States Postal Service Systems and methods for electronic message content identification
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6844456B2 (en) * 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
AU8838601A (en) * 2000-11-27 2002-06-03 Entremed Inc Antiangiogenic agents
JP2002241395A (ja) * 2001-02-16 2002-08-28 Taiho Yakuhin Kogyo Kk エストラ−４，６−ジエン−３，１７−ジオンの製造方法
US20050002900A1 (en) * 2001-11-06 2005-01-06 Grace Wong Method of treating estrogen responsive breast cancer
EP1450849A4 (en) * 2001-11-06 2005-06-29 Applied Research Systems METHOD FOR TREATING ENDOMETREOSE
CA2472379C (en) * 2002-01-21 2010-05-25 Akzo Nobel N.V. Process for the preparation of 7.alpha.-methylsteroids
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
WO2005018575A2 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Estrogen receptor modulators and uses thereof
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
TW200740442A (en) * 2005-08-29 2007-11-01 Taiho Pharmaceutical Co Ltd Therapeutic agent for hypertension
CN101296936B (zh) * 2005-10-27 2011-06-22 大鹏药品工业株式会社 生产甾族化合物的方法
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
ES2523821T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
RU2422455C1 (ru) * 2009-10-13 2011-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет ДИАЦЕТАТ РАЦЕМИЧЕСКОГО 3,17β-ДИГИДРОКСИ-7α,18-ДИМЕТИЛ-6-ОКСАЭСТРА-1,3,5( 10 ),8(9)-ТЕТРАЕНА, ОБЛАДАЮЩИЙ ОСТЕОПРОТЕКТОРНЫМ, ГИПОХОЛЕСТЕРИНЕМИЧЕСКИМ И АНТИОКСИДАНТНЫМ ДЕЙСТВИЕМ
WO2011133475A2 (en) * 2010-04-19 2011-10-27 Sri International Compositions and method for the treatment of multiple myeloma
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2013071214A1 (en) * 2011-11-10 2013-05-16 Sri International Synergistic anti-cancer activity of sr16388 with anti-mitotic drugs
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
WO2017010515A1 (ja) * 2015-07-14 2017-01-19 ノーベルファーマ株式会社 エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
US20170157143A1 (en) * 2015-12-02 2017-06-08 Helix Twelve Pharmaceuticals Corporation, Inc. Norpregnane derivatives for the risk reduction of breast cancer
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN107805247B (zh) * 2017-10-31 2020-09-29 上海长征富民金山制药有限公司 一种用于制备抗肾纤维化药物和/或抗慢性肾病药的β-咔啉化合物的制备工艺及其应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049015A (zh) * 1989-07-28 1991-02-06 先灵公司 14，17α-亚乙烯基雌三烯和14，17α-桥亚乙基雌三烯及其制备方法和在药物制备中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE84180C (enExample) *
FR943462A (fr) * 1946-03-08 1949-03-09 Ford Dispositif d'évacuation de l'eau pour glaces de voiture automobile
US2666769A (en) * 1952-09-27 1954-01-19 Searle & Co 17-glycolyl-estradiols
US2840581A (en) * 1956-12-17 1958-06-24 Upjohn Co Carbonyloxy steroids
NL294517A (enExample) * 1962-06-25 1900-01-01
FR1453210A (fr) 1963-05-08 1966-06-03 Roussel Uclaf Nouveaux aminostéroïdes et procédé de préparation
FR3031M (fr) 1963-05-08 1964-12-28 Roussel Uclaf Nouveau médicament notamment pour le traitement de l'hypercholestérolémie et des troubles en résultant.
FR3012M (fr) * 1963-05-13 1964-12-21 Roussel Uclaf Nouveaux médicaments doués notamment d'activité hypocholestérolémiante.
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
NL125069C (enExample) * 1963-12-24
FR1512326A (fr) * 1964-03-27 1968-02-09 Roussel Uclaf Nouveaux stéroïdes azotés et procédé de préparation
US3271392A (en) * 1965-09-14 1966-09-06 American Home Prod 17alpha-[3'-furyl]-estrogens
US3318917A (en) * 1965-11-12 1967-05-09 Searle & Co 17alpha-(4-alkoxy-3-buten-1-ynyl)estra-1, 3, 5(10)-triene-3, 17beta-diols and derivatives thereof
US3405147A (en) * 1966-02-25 1968-10-08 Searle & Co 17-phenylaliphatylestra-1, 3, 5(10)-trien-3-ols, 16-dehydro derivatives correspondingand esters thereof
US3398138A (en) * 1966-05-24 1968-08-20 American Home Prod Novel cardenolides and derivatives
US3448126A (en) * 1967-02-27 1969-06-03 Searle & Co 3-oxygenated 19-norpregna-1,3,5(10),17(20)-tetraen-21-als and enol esters thereof
US3536703A (en) * 1968-09-11 1970-10-27 Searle & Co N - (3 - alkoxy - 19 - norpregna - 1,3,5(10),17(20) - tetraen - 21 - yl)amines and derivatives thereof
GB1305752A (enExample) * 1970-03-06 1973-02-07
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
BE787343A (fr) * 1971-08-10 1973-02-09 Hoffmann La Roche Procede pour la preparation de 17-(2-halogenoethylidene)- steroides
US3927046A (en) * 1972-12-09 1975-12-16 Akzona Inc Novel 11,11-alkylidene steroids
US3859365A (en) * 1973-07-19 1975-01-07 Eastman Kodak Co Production of alkyl-substituted phenols from cyclohexenones
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
SU801517A1 (ru) * 1979-06-26 1988-12-30 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени 14 @ -оксиандрост-4-ен-3,17-диона
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
EP0243449A1 (en) * 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5274089A (en) * 1985-10-18 1993-12-28 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
DE3741800A1 (de) * 1987-12-07 1989-06-15 Schering Ag 17-halogenmethylen-estratriene
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
DK0471612T3 (da) * 1990-08-14 1999-02-22 Hoechst Marion Roussel Inc Nye 19-nor steroider med carbonkæde omfattende en amidgruppe i 11-beta-stillingen, fremgangsmåde til deres fremstilling, de
DE4132182A1 (de) * 1991-09-24 1993-03-25 Schering Ag 11(beta)-substituierte 14, 17-ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
CA2130754C (en) 1992-03-11 2005-02-08 Damian W. Grobelny Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
TW303299B (enExample) 1993-07-22 1997-04-21 Lilly Co Eli
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
US5593987A (en) 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049015A (zh) * 1989-07-28 1991-02-06 先灵公司 14，17α-亚乙烯基雌三烯和14，17α-桥亚乙基雌三烯及其制备方法和在药物制备中的应用

Also Published As

Publication number Publication date
DE69812433D1 (de) 2003-04-24
CA2281844A1 (en) 1999-07-08
EP1056768A2 (en) 2000-12-06
EP1056768B1 (en) 2003-03-19
NO20003254L (no) 2000-08-21
CN101130567B (zh) 2011-11-23
JP2001525855A (ja) 2001-12-11
BR9814435A (pt) 2004-08-10
CA2281844C (en) 2007-06-19
WO1999033859A9 (en) 1999-09-23
JP2007051148A (ja) 2007-03-01
US6054446A (en) 2000-04-25
HUP0100136A2 (hu) 2001-08-28
US6281205B1 (en) 2001-08-28
NO317978B1 (no) 2005-01-17
JP2007269797A (ja) 2007-10-18
JP3968114B2 (ja) 2007-08-29
KR100464739B1 (ko) 2005-01-05
EP2305694A2 (en) 2011-04-06
NO20003254D0 (no) 2000-06-22
WO1999033859A3 (en) 1999-12-23
DE69812433T2 (de) 2004-02-12
HUP0100136A3 (en) 2002-04-29
AU749597B2 (en) 2002-06-27
EP1847548A2 (en) 2007-10-24
JP4718512B2 (ja) 2011-07-06
JP4959276B2 (ja) 2012-06-20
EP1847548A3 (en) 2012-09-12
EP2305694A3 (en) 2013-04-17
IL136972A0 (en) 2001-06-14
EP1310509B1 (en) 2008-08-13
AU2010499A (en) 1999-07-19
EP1310509A2 (en) 2003-05-14
JP2007031446A (ja) 2007-02-08
EP1310509A3 (en) 2004-12-08
DE69839893D1 (de) 2008-09-25
AU749597C (en) 2003-02-20
US6455517B1 (en) 2002-09-24
CN1291196A (zh) 2001-04-11
WO1999033859A2 (en) 1999-07-08
CN101130567A (zh) 2008-02-27
RU2233288C2 (ru) 2004-07-27
KR20000075580A (ko) 2000-12-15
US20020032181A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
CN1332974C (zh) 抗雌激素甾族化合物、有关的药学组合物和使用方法
US6548491B2 (en) Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6503896B1 (en) Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US7388006B2 (en) Non-steroidal progesting
EP0946585B1 (fr) Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1998028324A9 (fr) Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
MXPA00006373A (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP1090027B1 (fr) Nouveaux 19-nor steroides 17-halogenes, procede et intermediaires de preparation, application comme medicaments et compositions pharmaceutiques les renfermant
Sane Synthesis of estrone sulfatase inhibitors as potential anti-breast cancer agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070822

Termination date: 20161223

CF01 Termination of patent right due to non-payment of annual fee